GlassScriptPhysician profile
Mouna Abouamara
NPI 1447324603
$1,412.08
in general payments reported to CMS, 2019-2025
28 companies · $16.50 in 2025
The $16.50 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $111 · 2020: $94.61 · 2021: $672 · 2022: $439 · 2023: $38.57 · 2024: $39.59 · 2025: $16.50.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $94.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $94.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $197.52 | 2021-2022 | |
| Janssen Biotech, INC. | $172.17 | 2019-2021 | |
| Glaxosmithkline, LLC. | $164.71 | 2021-2025 | Ojjaara |
| Novartis Pharmaceuticals Corporation | $125.45 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $79.73 | 2019-2022 | |
| Myovant Sciences INC. | $72.29 | 2021-2022 | |
| Beigene USA, INC. | $61.67 | 2021-2022 | |
| Lilly USA, LLC | $58.09 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $57.08 | 2020-2022 | |
| Eisai INC. | $52.56 | 2019-2022 | |
| Arbor Pharmaceuticals, INC. | $51.26 | 2020-2021 | |
| Pfizer INC. | $44.61 | 2019-2021 | |
| Genzyme Corporation | $41.75 | 2019-2022 | |
| Amgen INC. | $36.37 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23.32 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $20.51 | 2021 | |
| Kite Pharma, INC. | $20.08 | 2021 | |
| Adc Therapeutics America, INC. | $19.83 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $15.50 | 2020 | |
| Exelixis INC. | $14.83 | 2021 | |
| Genentech USA, INC. | $14.28 | 2022 | |
| Janssen Pharmaceuticals, INC | $13.69 | 2022 | |
| Dova Pharmaceuticals | $12.44 | 2019 | |
| Seagen INC. | $12.29 | 2019 | |
| Tersera Therapeutics LLC | $11.84 | 2021 | |
| Alexion Pharmaceuticals, INC. | $11.27 | 2021 | |
| Sirtex Medical INC | $6.94 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mouna Abouamara listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.